GenSight's GS010 misses in second Phase III for Leber hereditary optic neuropathy

GenSight Biologics S.A. (Euronext:SIGHT) reported that GS010 (rAAV2/2-ND4) missed the primary endpoint of improving visual acuity in the Phase III RESCUE trial to treat Leber hereditary optic neuropathy (LHON).

On the 39-patient trial's

Read the full 325 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE